Schizophrenia
Conditions
Brief summary
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing voices) and Negative symptoms (a reduction or absence of normal behaviors or emotions, i.e., unable to manage emotions, make decisions and relate to others). Other symptoms include reduced ability to recall and learn new information, difficulty with problem solving, or maintaining productive employment. The symptoms of schizophrenia may be due to an imbalance in chemicals in the brain, primarily dopamine and serotonin, which enables brain cells to communicate with each other. Asenapine is an investigational drug that may help to correct the imbalance in dopamine and serotonin. This is a 6 week study to test the efficacy and safety of asenapine and a comparator agent (olanzapine) in the treatment of patients with schizophrenia. Patients that complete this trial will have the option of continuing in an additional one year extension trial.
Interventions
DRUGasenapine
5 mg BID or 10mg BID
DRUGPlacebo
Placebo
DRUGolanzapine
olanzapine 15 mg QD
Sponsors
Organon and Co
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Currently suffering from an acute exacerbation of schizophrenia. Caregiver required.
Exclusion criteria
* Have an uncontrolled, unstable medical condition. Have any other psychiatric disorder other than schizophrenia as a primary diagnosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in total PANSS score at endpoint (6-week double-blind or last assessment after baseline) from baseline | Screen, baseline, Days 4,7,14,21,28,35,42 |
Secondary
| Measure | Time frame |
|---|---|
| Changes in PANSS subscale and Marder factor scores; CGI-S scores | Screen, baseline, Days 4,7,14,21,28,35,42 |
| CGI-I scores | Days 4,7,14,21,28,35,42 |
| Neurocognition and cognitive functioning | Baseline , day 42 |
| Anxiety | Baseline, day 42 |
| Suicidal thinking | Baseline, day 42 |
| Quality of life and patient functionality | Baseline, day 42 |
| Readiness to discharge, at scheduled assessments and endpoint from baseline | Baseline up to day 14 |
| Laboratory parameters | Baseline, Days 14,,28,,42 |
| Vital signs | Baseline, Days ,14,21,28,42 |
| Weight | Baseline, Days 14,,28,,42 |
| ECGs | Baseline, Days ,14,,28,,42 |
| Adverse events (including serious adverse events) | Screen, baseline, Days 4,7,14,21,28,35,42 and are are recorded continuously for AEs up to 7 days after endpoint |
| SAEs up to 30 days after endpoint | Screen, baseline, Days 4,7,14,21,28,35,42 and are are recorded continuously for AEs up to 30 days after endpoint |
| Extrapyramidal symptoms | Baseline, Days 4,7,14,21,28,35,42 |
Outcome results
None listed